Colony-stimulating factors for chemotherapy-induced febrile neutropenia

Abstract

Trusted evidence. Informed decisions. Better health.

Outcome of pediatric non‐Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA)

“…Granulocyte colony‐stimulating factor (G‐CSF) was not used systematically in our cohort. Although a meta‐analysis showed that its use in patients with chemotherapy‐induced neutropenia had no effect on overall mortality, these data were mostly obtained from patient series in developed countries, where the toxic mortality rates are already low, and a different impact might be seen in settings like ours, with higher mortality rates during neutropenia. Administering G‐CSF might also reduce the interval between cycles, thereby allowing higher‐intensity early doses, and its use is under consideration by our group.…”

Pharmacoeconomic analysis of the use of granulocyte colonystimulating factor drugs in prophylaxis of febrile neutropenia in cancer patients under healthcare settings in the Russian Federation

“…The main method of prophylaxis for febrile neutropenia or reduction of neutropenia duration after cytostatic therapy is prophylactic administration of granulocyte colony-stimulating factors (G-CSFs) -proteins that specifically stimulate hematopoietic progenitor cells of myeloid focus and accelerate production of normal neutrophils [1,2,7,16,17,18,21].…”

Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States

“…The decreasing mortality rates in the recent years could be attributed to the development of effective treatment modalities of febrile neutropenia and improvement in systems aimed at the early detection of sepsis patients [6]. The use of newer less toxic chemotherapy regimens along with prophylactic/therapeutic colony-stimulating factors may also play a role, although the benefit of therapeutic colony-stimulating factors for reducing mortality among patients with febrile neutropenia remains unclear [14,15]. Also, the differences in patient characteristics, comorbidities, and types of infection may also have accounted for some of the differences, which could not be separately analyzed in the present study.…”